Effectivity of Aβ Immunotherapies on Amyloid Plaque in Alzheimer’s Patients: A Close Examination
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6649Keywords:
Antibody, Antigen, Specificity, Monoclonal Antibody, Passive Immunotherapy, Anti-amyloid, Amyloid PlaqueAbstract
Alzheimer’s disease, alternatively named senile dementia, is a progressive neurodegenerative disease that affects 55 million people worldwide. As of this moment, the disease has no cure, with treatments being targeted towards the symptoms; specifically, slowing down clinical decline. Important treatments called Aβ immunotherapies are being developed right now. Due to the severity of this disease, efficiently researching and quickly finding cures that are effective is crucial. This paper will be focused on reviewing current passive Aβ immunotherapies and determining the effectiveness through the immunotherapy's effects on amyloid plaque concentration and clinical decline. Through this, it can be determined if research on further passive Aβ immunotherapies is warranted. Through reviewing numerous studies and cases from multiple hospitals and institutions, it is found that Donanemab and Lecanemab are effective, with both being shown to reduce clinical decline and amyloid plaque concentration. Crenezumab is shown to have potential, with further studies required to confirm efficacy. The other three immunotherapies, Bapineuzumab, Ponezumab, and Gantenerumab, were found to be ineffective lowering amyloid plaque and slowing clinical decline. Future research should focus on further studying the efficacy and safety of these passive immunotherapies. Through these results, further research on passive Aβ immunotherapies is warranted, and should be focused on in the future. Using these findings, the route in which further research on passive Aβ immunotherapies can be determined and be as efficient as possible.
Downloads
References or Bibliography
Alzheimer’s Association. (2014). Alzheimer’s disease facts and figures. Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/facts-figures#:~:text=in%20the%20U.S.-,Prevalence,living%20with%20Alzheimer%27s%20in%202023
Alzheimer’s Association. (2023). Donanemab for treatment of early alzheimer’s disease - news pending FDA Review. Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/treatments/donanemab#:~:text=Is%20donanemab%20FDA%2Dapproved%3F,expects%20action%20by%20early%202024
Alzheimer’s Association. (2007). What is alzheimer’s? Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/what-is-alzheimers
Alzheimer’s Disease Research. (2022). Alzheimer’s disease: Facts & figures. BrightFocus. https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures#:~:text=Worldwide%2C%20at%20least%2055%20million,Alzheimer
Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., Klein, G., Boada, M., Grimmer, T., Tomoaka, A., Perry, R. J., Turner, S., Watson, D., Woodward, M., Thanasopoulou, A., Lane, C., Baudler, M., Fox, N. C., Cummings, J. L., Fontoura, P., Doody, R. S. (2023). Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease. The New England journal of medicine, 389(1), 1862-1876. https://doi.org/10.1056/NEJMoa2304430
Beckman Coulter. (2018). What is the difference between active immunotherapy and passive immunotherapy?
Beckman Coulter Life Sciences. https://www.beckman.com/support/faq/research/active-immunotherapy-and-passive-immunotherapy
Blennow, K., Zetterberg, H., Rinne, J. O., Salloway, S., Wei, J., Black, R., Grundman, M., Liu, E. (2012). Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. Arch Neurol, 69(8):1002–1010. https://doi.org/10.1001/archneurol.2012.90
Cummings, J., Osse, A.M.L., Cammann, D., Powell, J., Chen, J. (2024) Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease. BioDrugs 38, 5–22. https://doi.org/10.1007/s40259-023-00633-2
der Forst, R. (2018). Antibodies: Structure, Function, Application. Antibodies-online.com.
https://www.antibodies-online.com/resources/16/1208/antibodies/
Doggrell, S. A. (2021) Still grasping at straws: donanemab in Alzheimer’s disease, Expert Opinion on Investigational Drugs, 30:8, 797-801. https://doi.org/10.1080/13543784.2021.1948010
Guthrie, H., Honig, L. S., Lin, H., Sink, K. M., Blondeau, K., Quartino, A., Dolton, M., Carrasco-Triguero, M., Lian, Q., Bittner, T., Clayton, D., Smith, J., Ostrowitzki, S. (2020). ‘Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks’. 967 – 979. https://doi.org/10.3233/JAD-200134
Jucker, M., & Walker, L. C. (2023). Alzheimer’s disease: From immunotherapy to immunoprevention. Cell Press, https://doi.org/10.1016/j.cell.2023.08.021
Khorassani, F., & Hilas, O. (2013). Bapineuzumab, an investigational agent for Alzheimer's disease. P & T : a peer-reviewed journal for formulary management, 38(2), 89–91. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628177/
Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson-Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M. (2017). Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study. Alzheimer's & dementia (New York, N. Y.), 3(3), 393–401. https://doi.org/10.1016/j.trci.2017.05.003
Landen, J. W., Zhao, Q., Cohen, S., Borrie, M., Woodward, M., Billing, C. B., Bales, K., Alvey, C., McCush, F., Yang, J., Kupiec, J. W., Bednar, M. M. (2013). Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study. Clinical Neuropharmacology 36(1):p 14-23, https://doi.org/10.1097/WNF.0b013e31827db49b
Lipman, N. S., Jackson, L. R., Trudel, L. J., Weis-Garcia, F. (2005). Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources, ILAR Journal, Volume 46, Issue 3, Pages 258–268, https://doi.org/10.1093/ilar.46.3.258
MBL. (2017). The role of antibodies. The role of antibodies | MBL Life Science -ASIA-. https://www.mblbio.com/bio/g/support/method/antibody-role.html
McDade, E., Cummings, J.L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M., Kramer, L. D., & Bateman, R. J. (2022). Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alz Res Therapy 14, 191 https://doi.org/10.1186/s13195-022-01124-2
Millipore Sigma. (2021). An introduction to antibodies: Antibody-antigen interaction. sigmaaldrich.com. https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/elisa/antibody-antigen-isnteraction
Mintun, M. A., Lo, A. C., Evans, C. D., Wessels, A. M., Ardayfio, P. A., Anderson, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M. (2021). Donanemab in Early Alzheimer’s Disease. The New England journal of medicine, 384(1), 1691-1704. https://doi.org/10.1056/NEJMoa2100708
National Human Genome Research Institution. (2024). Antibody. Genome.gov. https://www.genome.gov/genetics-glossary/Antibody
Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., Grimmer, T., Selkoe, D. J., Schneider, A., Blondeau, K., Hu, N., Quartino, A., Clayton, D., Dolton, M., Dang, Y., Ostaszewski, B., Sanabria-Bohórquez, S. M., Rabbia, M., Toth, B., Eichenlaub, U., Smith, J., Honigberg, L. A., Doody, R. S. (2022). Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA neurology, 79(11), 1113–1121. https://doi.org/10.1001/jamaneurol.2022.2909
Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., & SCarlet RoAD Investigators (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's research & therapy, 9(1), 95. https://doi.org/10.1186/s13195-017-0318-y
Pacific Immunology. (2013). Antibody specificity. https://www.pacificimmunology.com/resources/antibody-introduction/antibody-specificity/#:~:text=Each%20individual%20antibody%20protein%20is,variable%20region%20on%20the%20anhttps://www.pacificimmunology.com/resources/antibody-introduction/antibody-specificity/#:~:text=Each%20individual%20antibody%20protein%20is,variable%20region%20on%20the%20antibodytibody
Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., Cherrez-Ojeda, I. (2022). Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials. Healthcare, 11(1):32. https://doi.org/10.3390/healthcare11010032
Salloway, S., Honigberg, L.A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., Quartino, A., Clayton, D., Mortensen, D., Bittner, T., Ho, C., Rabe, C., Schauer, S. P., Wildsmith, K. R., Fuji, R. N., Suliman, S., Reiman, E. M., Chen, K., Paul, R. (2018). Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alz Res Therapy 10, 96. https://doi.org/10.1186/s13195-018-0424-5
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., Brashear, H. R. (2013). Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease. The New England journal of medicine, 370(1), 322-333. https://doi.org/10.1056/NEJMoa1304839
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2022). Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience. 14:870517. https://doi.org/10.3389/fnagi.2022.870517
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., Chen, H. (2022). Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener 11, 18. https://doi.org/10.1186/s40035-022-00292-3
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., Lobello, K., Li, D., McRae, T., Lucas, P., Evans, I., Booth, K., Luscan, G., Wyman, B. T., Hua, L., Yang, L., Brashear, H. R., Black, R. S. (2016). Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's research & therapy, 8(1), 18. https://doi.org/10.1186/s13195-016-0189-7
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. The New England journal of medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Published
How to Cite
Issue
Section
Copyright (c) 2024 Rithwik Tamilselvan; Mrs. Jothsna Kethar, Dr. Jobin Varkey, Ph.d
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
